Navigation Links
FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
Date:9/8/2008

evaluation", says Dr. Kundakovic, FluoroPharma's President. "We look forward to expanding our discovery and development of molecular imaging pharmaceuticals for PET to meet the growing needs in neurology and oncology."

About FluoroPharma

FluoroPharma, Inc., a privately-held molecular imaging company headquartered in Boston MA, engages in the discovery, development and commercialization of proprietary diagnostic imaging products for the PET market. The company's initial focus is the advancement of three imaging agents -- CardioPET, BFPET, and VasoPET -- for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for the diagnosis of certain types of cancer and for the diagnosis and treatment of Alzheimer's disease. For more information, please visit http://www.fluoropharma.com.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, y
'/>"/>

SOURCE FluoroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
2. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
3. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
4. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... group of national medical societies launched a multi-state advertising ... and Affordable Care Act, currently under consideration by the ... vote in the coming days. The groups are ... health care bill that is "bad medicine" for patients. ... care system needs reform - but the current Senate ...
(Date:12/16/2009)... WORTH, Texas, Dec. 16 Wound ... a rapidly growing provider of specialty medical ... operating subsidiary is moving toward productization of ... The company currently anticipates products to be ... market, estimated to be a multi-billion dollar ...
(Date:12/16/2009)... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an ... $1 million in 12% per annum short term debt ... an initial drawdown of $500,000, with accrued interest and ... $500,000 with accrued interest and principal repayable in one ... becoming cashflow positive for any calendar month prior to ...
Breaking Medicine Technology:Physician Groups Oppose Current Senate Health Care Reform Bill 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2Apollo Health Street Collaborates with Client to Develop a CCHIT Certified 08 Ambulatory EMR 48571 1Apollo Health Street Collaborates with Client to Develop a CCHIT Certified 08 Ambulatory EMR 48571 2Highmark Caring Place To Honor Midstate Volunteers 48566 1Highmark Caring Place To Honor Midstate Volunteers 48566 2Highmark Caring Place To Honor Midstate Volunteers 48566 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 1New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 2New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 4New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 5New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 6
... 26, 2007 - A new study published,in ... Child Neurology indicates,that a treatment from Medtronic, ... palsy improves their quality of life and ... findings of this Medtronic-sponsored study should,expand access ...
... doctors say they are outraged,over recent media ... hormone to treat a hormone deficiency often ... 2007 /PRNewswire/ -- The adult,use of human ... of a recent New,York Times article about ...
Other Medicine Technology:Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 2Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 3Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 4Doctors Outraged Over Growth Hormone Controversy 2
(Date:12/16/2009)... In an advance that could help ease health and ... reporting development of technology for changing the behavior of ... gateway into the environment. Their study was published in ... Helen Jarvie from the UK Centre for Ecology and ... in the production of nanoparticles particles less than ...
(Date:12/16/2009)... The omega-3 essential fatty acids commonly found in ... overload, according to research published by the American ... the information-processing problems found in people with schizophrenia; ... and other afflictions of the nervous system. ... Behavioral Neuroscience , provides more evidence that fish ...
(Date:12/16/2009)... and Encourage Access to Quality, Cost-Effective Care , ... ... Congress have debated the best ways to rein in runaway costs ... An important part of the ongoing discussion includes how to ... providers besides doctors of medicine (MDs) or osteopathy (DOs). In ...
(Date:12/16/2009)... no direct link has been found, , , WEDNESDAY, Dec. ... -- commonly linked to food poisoning and the stomach ... the cause of some urinary tract infections. , Researchers ... chicken from stores and restaurants and in women with ... germs were transmitted directly to the women through the ...
(Date:12/16/2009)... Reduction Therapy or NSRTSM is found very effective in the ... allergies, asthma, migraines, chronic fatigue and a wide array of ... are using this holistic therapy including over 50 branded BioVeda ... ... Minneapolis, MN (Vocus) December 14, 2009 -- BioVeda Health and ...
Breaking Medicine News(10 mins):Health News:Behavior modification could ease concerns about nanoparticles 2Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5
... ... growth since 2007, INDIANAPOLIS, May 30 MDwise employees ... plan -- surpassing the 300,000 mark in,membership., In addition to the ... employee base by 182 percent -- going from just,over 50 employees at ...
... YORK, May 30 We know ... to,our skin -- but what about ... Listen to this report from Transitions ... journalists can access video, audio, text, ...
... radicals from hypertension, study finds , , FRIDAY, May 30 ... BH4 may hold promise as a treatment for people with ... BH4 is used to treat a genetic disorder called phenylketonuria ... a molecule called phenylalanine can cause brain damage. , In ...
... Aspects of New Jersey Cases, WHITEHOUSE STATION, N.J., May ... gratified that a Texas appeals court,overturned the August 2005 verdict ... judgment in favor of Merck in the VIOXX product liability,case ... go to trial after the,Company voluntarily removed the medicine from ...
... the University of Calgary shows that smoking while pregnant, ... increased risk of Sudden Infant Death Syndrome (SIDS). Increased ... time or increasing the room temperature can affect the ... to SIDS include babies sleeping in a belly-down position ...
... men,s sexual appetite. But stimulating new research in the ... the eye. A recent study shows that men who ... when they were making decisions about money, soda, and ... and Luk Warlop (KULeuven, Belgium) found that the desire ...
Other Medicine News:Health News:MDwise Enrollment Exceeds 300,000 Members 2Health News:Genetic Disorder Drug Helps Reverse Heart Muscle Enlargement 2Health News:Merck Wins Appeal of First VIOXX(R) Case to go to Trial 2Health News:Merck Wins Appeal of First VIOXX(R) Case to go to Trial 3Health News:New research shows overheating newborns can increase the risk of SIDS 2
The Kowa Non-Contact Tonometer KT-800 comes with a one year parts and labor warranty....
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... SpaTouch Pro, powered by LHE, ... multi-application platform. A powerful tool in ... works fast, providing noticeable results usually ... safety in each of its applications, ...
SPR treats pigmented and vascular lesions, skin aging, sun damaged skin and fine lines and wrinkles with clinically proven LHE technology....
Medicine Products: